These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 28504613

  • 1. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [Abstract] [Full Text] [Related]

  • 2. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
    Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y.
    Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
    [Abstract] [Full Text] [Related]

  • 4. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK.
    Oncotarget; 2015 Nov 03; 6(34):36003-18. PubMed ID: 26416352
    [Abstract] [Full Text] [Related]

  • 5. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb 03; 36(1):25-29. PubMed ID: 28157429
    [Abstract] [Full Text] [Related]

  • 6. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
    Kato Y, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2018 Nov 03; 37(5):218-223. PubMed ID: 30362926
    [Abstract] [Full Text] [Related]

  • 7. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, Asano T, Sayama Y, Hosono H, Suzuki H, Kawada M, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2020 Oct 03; 39(5):167-174. PubMed ID: 33085938
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
    Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y.
    Cancer Med; 2017 Feb 03; 6(2):382-396. PubMed ID: 28101903
    [Abstract] [Full Text] [Related]

  • 13. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
    Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2016 Jun 03; 35(3):155-62. PubMed ID: 27328060
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 03; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Takei J, Kaneko MK, Ohishi T, Hosono H, Nakamura T, Yanaka M, Sano M, Asano T, Sayama Y, Kawada M, Harada H, Kato Y.
    Oncol Rep; 2020 Nov 03; 44(5):1949-1960. PubMed ID: 33000243
    [Abstract] [Full Text] [Related]

  • 18. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
    Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2015 Oct 03; 34(5):310-7. PubMed ID: 26492618
    [Abstract] [Full Text] [Related]

  • 19. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
    Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2015 Jun 03; 34(3):174-80. PubMed ID: 26090595
    [Abstract] [Full Text] [Related]

  • 20. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.
    Cancer Sci; 2012 Nov 03; 103(11):1913-9. PubMed ID: 22816430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.